Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead
Tuberculosis (TB) remains as the second most-deadly infection right behind the HIV/AIDS. Actually, in 2016, TB incidence was estimated in 10.4 million cases. Although an efficient and low-cost TB pharmacotherapy has been available for the last 50 years, the development of multi- and extra-drug-resis...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | JOUR |
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/20.500.12110/paper_07248741_v35_n11_p_Grotz |
| Aporte de: |
| id |
todo:paper_07248741_v35_n11_p_Grotz |
|---|---|
| record_format |
dspace |
| spelling |
todo:paper_07248741_v35_n11_p_Grotz2023-10-03T15:37:13Z Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead Grotz, E. Tateosian, N. Amiano, N. Cagel, M. Bernabeu, E. Chiappetta, D.A. Moretton, M.A. active targeting nanotechnology respirable nanocarriers tuberculosis liposome nanoparticle niosome tuberculostatic agent tuberculostatic agent cost disease carrier disease eradication drug delivery system drug therapy human incidence micelle nanomedicine nanotechnology nonhuman polymerization prevalence priority journal randomized controlled trial (topic) Review socioeconomics tuberculosis animal antibiotic resistance chemistry drug development drug effect Mycobacterium tuberculosis nanotechnology pathology procedures tuberculosis Animals Antitubercular Agents Drug Delivery Systems Drug Discovery Drug Resistance, Bacterial Humans Liposomes Micelles Mycobacterium tuberculosis Nanomedicine Nanoparticles Nanotechnology Tuberculosis Tuberculosis (TB) remains as the second most-deadly infection right behind the HIV/AIDS. Actually, in 2016, TB incidence was estimated in 10.4 million cases. Although an efficient and low-cost TB pharmacotherapy has been available for the last 50 years, the development of multi- and extra-drug-resistant Mycobacterium tuberculosis (Mtb) strains has put on the spot the necessity of improved TB regimens. In this framework, this review article presents the main relevant research outcomes of nanotechnology in TB. The novel delivery systems for antituberculosis drugs have been discussed. Moreover, the active-targeted nanomedicines to the Mtb reservoirs enlighten the possibility to eradicate low-replicant mycobacteria and diminish latent TB. Finally, we present an overview of the TB socio-economic impact and the cost-related features of TB regimens associated with the use of nanoformulations. © 2018, Springer Science+Business Media, LLC, part of Springer Nature. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_07248741_v35_n11_p_Grotz |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
active targeting nanotechnology respirable nanocarriers tuberculosis liposome nanoparticle niosome tuberculostatic agent tuberculostatic agent cost disease carrier disease eradication drug delivery system drug therapy human incidence micelle nanomedicine nanotechnology nonhuman polymerization prevalence priority journal randomized controlled trial (topic) Review socioeconomics tuberculosis animal antibiotic resistance chemistry drug development drug effect Mycobacterium tuberculosis nanotechnology pathology procedures tuberculosis Animals Antitubercular Agents Drug Delivery Systems Drug Discovery Drug Resistance, Bacterial Humans Liposomes Micelles Mycobacterium tuberculosis Nanomedicine Nanoparticles Nanotechnology Tuberculosis |
| spellingShingle |
active targeting nanotechnology respirable nanocarriers tuberculosis liposome nanoparticle niosome tuberculostatic agent tuberculostatic agent cost disease carrier disease eradication drug delivery system drug therapy human incidence micelle nanomedicine nanotechnology nonhuman polymerization prevalence priority journal randomized controlled trial (topic) Review socioeconomics tuberculosis animal antibiotic resistance chemistry drug development drug effect Mycobacterium tuberculosis nanotechnology pathology procedures tuberculosis Animals Antitubercular Agents Drug Delivery Systems Drug Discovery Drug Resistance, Bacterial Humans Liposomes Micelles Mycobacterium tuberculosis Nanomedicine Nanoparticles Nanotechnology Tuberculosis Grotz, E. Tateosian, N. Amiano, N. Cagel, M. Bernabeu, E. Chiappetta, D.A. Moretton, M.A. Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead |
| topic_facet |
active targeting nanotechnology respirable nanocarriers tuberculosis liposome nanoparticle niosome tuberculostatic agent tuberculostatic agent cost disease carrier disease eradication drug delivery system drug therapy human incidence micelle nanomedicine nanotechnology nonhuman polymerization prevalence priority journal randomized controlled trial (topic) Review socioeconomics tuberculosis animal antibiotic resistance chemistry drug development drug effect Mycobacterium tuberculosis nanotechnology pathology procedures tuberculosis Animals Antitubercular Agents Drug Delivery Systems Drug Discovery Drug Resistance, Bacterial Humans Liposomes Micelles Mycobacterium tuberculosis Nanomedicine Nanoparticles Nanotechnology Tuberculosis |
| description |
Tuberculosis (TB) remains as the second most-deadly infection right behind the HIV/AIDS. Actually, in 2016, TB incidence was estimated in 10.4 million cases. Although an efficient and low-cost TB pharmacotherapy has been available for the last 50 years, the development of multi- and extra-drug-resistant Mycobacterium tuberculosis (Mtb) strains has put on the spot the necessity of improved TB regimens. In this framework, this review article presents the main relevant research outcomes of nanotechnology in TB. The novel delivery systems for antituberculosis drugs have been discussed. Moreover, the active-targeted nanomedicines to the Mtb reservoirs enlighten the possibility to eradicate low-replicant mycobacteria and diminish latent TB. Finally, we present an overview of the TB socio-economic impact and the cost-related features of TB regimens associated with the use of nanoformulations. © 2018, Springer Science+Business Media, LLC, part of Springer Nature. |
| format |
JOUR |
| author |
Grotz, E. Tateosian, N. Amiano, N. Cagel, M. Bernabeu, E. Chiappetta, D.A. Moretton, M.A. |
| author_facet |
Grotz, E. Tateosian, N. Amiano, N. Cagel, M. Bernabeu, E. Chiappetta, D.A. Moretton, M.A. |
| author_sort |
Grotz, E. |
| title |
Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead |
| title_short |
Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead |
| title_full |
Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead |
| title_fullStr |
Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead |
| title_full_unstemmed |
Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead |
| title_sort |
nanotechnology in tuberculosis: state of the art and the challenges ahead |
| url |
http://hdl.handle.net/20.500.12110/paper_07248741_v35_n11_p_Grotz |
| work_keys_str_mv |
AT grotze nanotechnologyintuberculosisstateoftheartandthechallengesahead AT tateosiann nanotechnologyintuberculosisstateoftheartandthechallengesahead AT amianon nanotechnologyintuberculosisstateoftheartandthechallengesahead AT cagelm nanotechnologyintuberculosisstateoftheartandthechallengesahead AT bernabeue nanotechnologyintuberculosisstateoftheartandthechallengesahead AT chiappettada nanotechnologyintuberculosisstateoftheartandthechallengesahead AT morettonma nanotechnologyintuberculosisstateoftheartandthechallengesahead |
| _version_ |
1807316558242906112 |